AKT1 and neoplasm: Zhong et al. [173] and Shen et al. [175] demonstrated that miR-222 promoted resistance to both DOX and DTX by targeting PTEN and indirectly inhibiting FOXO1, which is an AKT pathway inhibitor implicated in tumor suppressor functions such as cell cycle, apoptosis regulation, and cell differentiation.